[Experiences with sodium 2-propyl valerate (Depakine) in the treatment of epilepsy].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002220:Carbamazepine / Q000627:therapeutic use; D002557:Cerebrospinal Fluid Shunts; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000628:therapy; D007223:Infant; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D013036:Spasms, Infantile / Q000188:drug therapy; D014631:Valerates / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
D014631:Valerates; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital
Ervaringen met valproïnezuur (Depakine) bij de behandeling van epilepsie